RemeGen Statistics

Total Valuation

RemeGen has a market cap or net worth of HKD 26.90 billion. The enterprise value is 28.93 billion.

Market Cap	26.90B
Enterprise Value	28.93B

Important Dates

The last earnings date was Friday, March 28, 2025.

Earnings Date	Mar 28, 2025
Ex-Dividend Date	n/a

Share Statistics

RemeGen has 536.56 million shares outstanding. The number of shares has decreased by -0.35% in one year.

Current Share Class	n/a
Shares Outstanding	536.56M
Shares Change (YoY)	-0.35%
Shares Change (QoQ)	-0.46%
Owned by Insiders (%)	11.57%
Owned by Institutions (%)	38.99%
Float	338.14M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	14.72
PB Ratio	12.73
P/TBV Ratio	13.71
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-18.51
EV / Sales	15.83
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-19.71

Financial Position

The company has a current ratio of 1.05, with a Debt / Equity ratio of 1.34.

Current Ratio	1.05
Quick Ratio	0.64
Debt / Equity	1.34
Debt / EBITDA	n/a
Debt / FCF	-1.94
Interest Coverage	-19.68

Financial Efficiency

Return on equity (ROE) is -54.15% and return on invested capital (ROIC) is -19.04%.

Return on Equity (ROE)	-54.15%
Return on Assets (ROA)	-16.15%
Return on Invested Capital (ROIC)	-19.04%
Return on Capital Employed (ROCE)	-42.91%
Revenue Per Employee	609,215
Profits Per Employee	-521,037
Employee Count	2,999
Asset Turnover	0.31
Inventory Turnover	0.49

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +37.83% in the last 52 weeks. The beta is 0.37, so RemeGen's price volatility has been lower than the market average.

Beta (5Y)	0.37
52-Week Price Change	+37.83%
50-Day Moving Average	21.96
200-Day Moving Average	16.76
Relative Strength Index (RSI)	77.63
Average Volume (20 Days)	11,725,765

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, RemeGen had revenue of HKD 1.83 billion and -1.56 billion in losses. Loss per share was -2.91.

Revenue	1.83B
Gross Profit	1.46B
Operating Income	-1.52B
Pretax Income	-1.56B
Net Income	-1.56B
EBITDA	-1.27B
EBIT	-1.52B
Loss Per Share	-2.91

Full Income Statement

Balance Sheet

The company has 811.42 million in cash and 2.84 billion in debt, giving a net cash position of -2.03 billion or -3.78 per share.

Cash & Cash Equivalents	811.42M
Total Debt	2.84B
Net Cash	-2.03B
Net Cash Per Share	-3.78
Equity (Book Value)	2.11B
Book Value Per Share	3.94
Working Capital	118.65M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -1.19 billion and capital expenditures -282.31 million, giving a free cash flow of -1.47 billion.

Operating Cash Flow	-1.19B
Capital Expenditures	-282.31M
Free Cash Flow	-1.47B
FCF Per Share	-2.74

Full Cash Flow Statement

Margins

Gross margin is 79.81%, with operating and profit margins of -82.98% and -85.53%.

Gross Margin	79.81%
Operating Margin	-82.98%
Pretax Margin	-85.53%
Profit Margin	-85.53%
EBITDA Margin	-69.53%
EBIT Margin	-82.98%
FCF Margin	n/a

Dividends & Yields

RemeGen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.35%
Shareholder Yield	0.35%
Earnings Yield	-5.81%
FCF Yield	-5.46%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

RemeGen has an Altman Z-Score of 1.42. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.42
Piotroski F-Score	n/a